



# Neothetics

## NEOTHETICS TO PRESENT AT THE 16<sup>TH</sup> ANNUAL NEEDHAM HEALTHCARE CONFERENCE

**SAN DIEGO, March 29, 2017**— Neothetics, Inc. (NASDAQ: NEOT) today announced that Susan A. Knudson, Neothetics' Chief Financial Officer, will present at the 16<sup>th</sup> Annual Needham Healthcare Conference on Wednesday, April 5<sup>th</sup> at 12:50 PM, Eastern Time at the Westin Grand Central Hotel in New York City.

To receive Neothetics' press releases and other investor information, please go to the Investor Relations page of the company's website at [investors.neothetics.com](http://investors.neothetics.com) and register for [email alerts](#).

### About LIPO-202

LIPO-202 is a proprietary, first-in-class injectable formulation of the well-known long-acting  $\beta$ 2-adrenergic receptor agonist, salmeterol xinafoate, which is an active ingredient of FDA-approved inhaled products such as SEREVENT DISKUS<sup>®</sup>, ADVAIR HFA<sup>®</sup> and ADVAIR DISKUS<sup>®</sup>. Our studies suggest that salmeterol xinafoate activates  $\beta$ 2-adrenergic receptors on fat cells, triggering the body's natural process of metabolizing stored triglycerides (fat) resulting in a reduction in size and volume of the fat cells in the treatment area without damage of nearby tissues. LIPO-202 has an extremely favorable safety profile, with little to no adverse post treatment effects. LIPO-202 is being evaluated for the reduction of submental fat commonly referred to as a double-chin.

### About Neothetics, Inc.

Neothetics is a San Diego based clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. Our initial focus is on localized fat reduction and body contouring. Our lead product candidate, LIPO-202, is a first-in-class injectable formulation of the long-acting  $\beta$ 2-adrenergic receptor agonist, salmeterol xinafoate, which is an active ingredient in the U.S. Food and Drug Administration, or FDA, approved inhaled products SEREVENT DISKUS<sup>®</sup>, ADVAIR HFA<sup>®</sup> and ADVAIR DISKUS<sup>®</sup>. For more information on Neothetics, please visit [www.neothetics.com](http://www.neothetics.com). Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.

### Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the ability to develop a modified formulation of LIPO-202, timing of conducting and obtaining results from Phase 2 trials and proof of concept study with a modified formulation of LIPO-202, whether our modified formulation of LIPO-202 is able to demonstrate positive results, Neothetics' plans to research, develop and commercialize LIPO-202 and other product candidates, our expectations regarding the potential market size and opportunity

of LIPO-202, as well as expected timing for reporting results from clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Neothetics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with clinical trials, such as the ability to timely initiate clinical trials and enroll a sufficient number of patients on a timely basis into clinical trials, the extent to which top-line data is available and whether the clinical trials achieve positive results, product development activities, obtaining regulatory approval to commercialize LIPO-202 and other product candidates, Neothetics' use of cash, and the need to raise additional funding, when needed, in order to conduct our clinical trials and other business, the degree of market acceptance of LIPO-202 by physicians, patients and others in the medical community, our reliance on third parties, including third-party suppliers for manufacturing and distribution of products, regulatory developments in the United States and foreign countries, Neothetics' ability to obtain and maintain intellectual property protection for LIPO-202 and its product candidates, competition in the aesthetics industry and other market conditions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Neothetics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC available at [www.sec.gov](http://www.sec.gov), including without limitation, Neothetics' Form 10-K for the year ended December 31, 2016 and subsequent Quarterly Reports on Form 10-Q.

COMPANY CONTACTS:

Susan A. Knudson  
Chief Financial Officer  
858-500-7780  
sknudson@neothetics.com

Fara Berkowitz, R.Ph, Pharm.D  
Senior Director, Investor Relations and Corporate Development  
646-494-1589  
fberkowitz@neothetics.com

###